Annals of Oncology

Volume 27, Supplement 6, 1 October 2016, Page vi350

Submitted abstracts

Head and neck cancer

1016TiP - A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

• Previous article in issue
• Next article in issue